Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II)

Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II): a double-blind, cluster-randomized control trial for integrated control of malaria.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR201907479787308

Enrollment

4700

Registered

2019-07-15

Start date

2019-06-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

Ivermectin

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Residence in selected study village Able to understand the information and willing to give consent or assent (age 12-18) and parent/guardian consent if study participant age is < 18 years of age.

Exclusion criteria

Exclusion criteria: Residence outside of the study village Height < 90 cm (*note: if subject becomes =90cm over course the trial, this exclusion criteria will no longer be valid in subsequent MDA) Current treatment with SP+AQ as part of SMC (restricted to children 3-48 months old) (*note: if subject discontinuous SP+AQ treatment because they become older than 48 months over course the trial, this exclusion criteria will no longer be valid in subsequent MDA) Permanent disability or serious medical illness that prevents or impedes study participation and/or comprehension Pregnancy (screened for in women of child-bearing age [ages 15-45] using a pregnancy urine rapid test [e.g. SD Bioline hCG] the week prior to each MDA) Breast feeding if infant is within 1 week of birth Known allergy to ivermectin Possibility of Loa loa infection as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria, and Sudan. Enrolled in any other active clinical trials

Design outcomes

Primary

Measure	Time frame
Malaria incidence Incidence of uncomplicated malaria episodes in enrolled village children = 10 years of age	—

Secondary

Measure	Time frame
Harms Incidence of harms in the study population over the course of the intervention period;Entomological indices Blood fed mosquito mortality, entomological inoculation rate, and human exposure to anopheline mosquito bites over time will be compared between intervention and control arms;3. Parasitological indices Plasmodium spp. prevalence, density, multiplicity of infection and molecular force of infection will be compared between intervention and control arms	—

Measure

Time frame

Harms Incidence of harms in the study population over the course of the intervention period;Entomological indices Blood fed mosquito mortality, entomological inoculation rate, and human exposure to anopheline mosquito bites over time will be compared between intervention and control arms;3. Parasitological indices Plasmodium spp. prevalence, density, multiplicity of infection and molecular force of infection will be compared between intervention and control arms

—

Countries

Burkina Faso

Contacts

Public ContactFabrice SOME

STUDY COORDINATOR

afabricesome@yahoo.fr+22670011380

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026